Combined assessment of reflow and collateral blood flow by myocardial contrast echocardiography after acute reperfused myocardial infarction

F Leclercq, P Messner-Pellenc, Q Descours, J-P Daures, J-L Pasquié, F-X Hager, J-M Davy, R Grolleau-Raoux

Abstract

Objective—To evaluate the combined assessment of reflow and collateral blood flow by myocardial contrast echocardiography after myocardial infarction.

Design—Myocardial contrast echocardiography was performed in patients with acute myocardial infarction shortly after successful coronary reperfusion (TIMI 3 patency) by direct angioplasty. Collateral flow was assessed before coronary angioplasty, and contrast reflow was evaluated 15 minutes after reperfusion. The presence of contractile reserve was assessed by low dose dobutamine echocardiography (5 to 15 µg/kg/min) at (mean (SD)) 3 (2) days after myocardial infarction. Recovery of segmental function (myocardial viability) was evaluated by resting echocardiography at a two month follow up. The study was prospective.

Patients—35 consecutive patients referred for acute transmural myocardial infarction.

Results—Contrast reflow was observed in 20 patients (57%) and collateral flow in 14 (40%). Contrast reflow and collateral contrast flow were both correlated with reversible dysfunction on initial dobutamine echocardiography and at follow up (p < 0.05). The presence of reflow or collateral flow on myocardial contrast echocardiography was a highly sensitive (100%) but weakly specific (60%) indicator of segmental dysfunction recovery. Simultaneous presence of contrast reflow and collateral flow was more specific of reversible dysfunction than reflow alone (90% v 60%).

Conclusions—Combined assessment of reflow and collateral blood flow enhanced the sensitivity of myocardial contrast echocardiography in predicting myocardial viability after acute, reperfused myocardial infarction. The simultaneous presence of reflow and collateral blood flow was highly specific of recovery of segmental dysfunction.

(Heart 1999;82:62–67)

Methods

STUDY POPULATION

Myocardial contrast echocardiography was performed in consecutive patients admitted for their first acute transmural myocardial infarction from January to June 1996. The diagnosis of acute myocardial infarction was made on the basis of chest pain of more than 30 minutes’ duration, ST segment elevation of more than 2 mm in two contiguous ECG leads, and a more than threefold increase in serum creatine...
Reflow and collateral flow assessed by contrast echocardiography

CARDIAC CATHETERISATION
We only studied patients with a totally occluded infarct related coronary artery at the time of cardiac catheterisation. All patients showed successful coronary reflow on direct angioplasty, defined by TIMI (thrombolysis in myocardial infarction) grade 3 flow and a residual coronary stenosis of less than 30%. According to the TEAM-2 study (second multicenter thrombolytic trials of eminase in acute myocardial infarction), patients who achieved TIMI grade 2 flow were not considered to have myocardial salvage with reperfusion and were therefore not included in the study.11 The collateral flow was angiographically graded as absent (no collateral vessels seen) or present (partial or complete filling of the infarct related artery). The right anterior oblique view of the left ventriculogram was used for assessment of global left ventricular function. Left ventricular ejection fraction was calculated from the volumes obtained using the area-length method.

MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY
Myocardial contrast echocardiography was performed by manually injecting in the coronary artery a small amount (2 to 3 ml) of sonicated ioxaglate (Hexabrix 320, Guerbet, France) during simultaneously performed transthoracic cross sectional echocardiography in multiple views (mid-papillary short axis view, and apical views of two and four chambers) using a 16 segment model.12 A Hewlett-Packard Sonos 2000 machine with a 2.5 MHz probe was used (Hewlett-Packard Inc, Andover, Massachusetts, USA).

Echographic images were recorded before and after reperfusion of the culprit coronary artery. Before reperfusion, the microbubble suspension was injected into the contralateral non-infarct-related coronary artery in order to assess the presence of contrast collateral flow, which was considered significant when supplying more than 50% of the risk area.10 The suspension was then injected into the infarct related artery before and 15 minutes after successful reperfusion by direct angioplasty, in order to evaluate the risk and no reflow areas, respectively.

For analysis of contrast images, we used the end diastolic frame of the postinjection cycle showing the best delineation between contrast enhanced and non-enhanced myocardium.7 The risk area was determined as the number of segments showing no contrast enhancement before reperfusion.13 To minimise the effect of left to left collaterals in patients with occlusion of the left anterior descending coronary artery, we analysed the first end diastolic image after injection of contrast into the left main coronary artery.11 No reflow was defined when the residual contrast defect exceeded 25% of the risk area 15 minutes after angiographic reperfusion. We therefore defined adequate reflow when more than 75% of the risk area was opacified with contrast.7 We refer to this as the “strong” criterion. We also evaluated a weaker criterion of reflow, defined when more than 50% of the risk area was opacified with contrast (“weak criterion”).13

LOW DOSE DOBUTAMINE ECHOCARDIOGRAPHY
Dobutamine echocardiography was performed between two and five days after myocardial infarction (average three days) by two experienced operators using a 16 segment left ventricular model.12 β Blocking agents were withdrawn 24 hours before the test. Dobutamine was infused in a 1 mg/l solution in three 5 minute periods at 5, 10, and 15 µg/kg/min. In the setting of acute myocardial infarction without limiting coronary stenosis, related to successful angioplasty, high doses of dobutamine were not used.14 According to the recommendations of the American Society of Echocardiography,11 a semiquantitative score was assigned to each segment: 1, normokinesia or hyperkinesia; 2, hypokinesia; 3, akinesia; 4, dyskinesia. A wall motion score index was obtained by dividing the sum of the individual segmental scores by the number of segments analysed. Reversible contractile dysfunction was defined as improved wall motion in at least two contiguous dyssynergic segments or in one segment if only two segments were basically dyssynergic.16 17 A change in wall motion from dyskinesia to akinesia or vice versa was considered to indicate unchanged segmental function.

ECHOCARDIOGRAPHIC FOLLOW UP
Follow up resting echocardiography was performed in each patient within two months of hospital discharge (range 28 to 60 days) in order to evaluate recovery of regional dysfunction. All echocardiograms were blindly reviewed on videotape by two independent observers.

STATISTICAL ANALYSIS
All data are expressed as mean (SD). Sensitivity, specificity, and accuracy were evaluated using standard definitions and expressed in percentages. Fisher’s exact test or the χ² test was performed to compare categorical variables between different groups of patients in relation to the prediction of reversible dysfunction at follow up. For comparison between continuous variables, a non-parametric

Table 1  Clinical and angiographic characteristics of the study patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number of patients</th>
<th>Mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>35</td>
<td>59 (24 to 78)</td>
</tr>
<tr>
<td>Mean (range) age (years)</td>
<td>Male</td>
<td>27 (77)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Hypertension</td>
<td>7 (20)</td>
</tr>
<tr>
<td>Mean (range) LVEF (%)</td>
<td>9 (26)</td>
<td></td>
</tr>
<tr>
<td>Anterior infarction</td>
<td>Mean (range) LVEF (%)</td>
<td>20 (57)</td>
</tr>
<tr>
<td>Mean (range) LVEF (%)</td>
<td>52 (20 to 70)</td>
<td></td>
</tr>
<tr>
<td>LV EF ≤ 35%</td>
<td>8 (23)</td>
<td></td>
</tr>
<tr>
<td>Infarct related artery</td>
<td>Left anterior descending</td>
<td>19 (54)</td>
</tr>
<tr>
<td>Left main</td>
<td>Right coronary artery</td>
<td>15 (43)</td>
</tr>
<tr>
<td>Multivessel disease</td>
<td>Angiographic collateral blood flow</td>
<td>17 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11 (31)</td>
</tr>
</tbody>
</table>

Values are n (%) unless otherwise stated.
LVEF, left ventricular ejection fraction.
Table 2  Clinical and angiographic characteristics of patients studied by myocardial contrast echocardiography: reflow and collateral blood flow assessment

<table>
<thead>
<tr>
<th></th>
<th>Reflow</th>
<th>No reflow</th>
<th>Collateral flow (+)</th>
<th>Collateral flow (-)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>20</td>
<td>15</td>
<td>14</td>
<td>21</td>
</tr>
<tr>
<td>Mean (range) age (years)</td>
<td>63 (24 to 76)</td>
<td>56 (44 to 78)</td>
<td>51 (32 to 76)</td>
<td>56 (24 to 78)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5 (23)</td>
<td>4 (26)</td>
<td>4 (28)</td>
<td>5 (24)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4 (20)</td>
<td>3 (20)</td>
<td>3 (21)</td>
<td>4 (19)</td>
</tr>
<tr>
<td>Anterior infarct location</td>
<td>11 (55)</td>
<td>9 (60)</td>
<td>8 (57)</td>
<td>12 (57)</td>
</tr>
<tr>
<td>Multivessel disease</td>
<td>8 (40)</td>
<td>9 (60)</td>
<td>7 (50)</td>
<td>10 (48)</td>
</tr>
<tr>
<td>Angiographic collateral flow</td>
<td>6 (30)</td>
<td>5 (33)</td>
<td>4 (28)</td>
<td>7 (33)</td>
</tr>
<tr>
<td>Mean (range) LVEF (%)</td>
<td>61* (50 to 73)</td>
<td>43* (20 to 65)</td>
<td>55 (39 to 73)</td>
<td>66 (20 to 73)</td>
</tr>
<tr>
<td>Mean delay of reperfusion (min)</td>
<td>230</td>
<td>310</td>
<td>270</td>
<td>340</td>
</tr>
</tbody>
</table>

Values are n (%) unless otherwise stated.
*p < 0.05.
LVEF, left ventricular ejection fraction.

Kruskal–Wallis test was used. Differences between comparisons were considered significant at p value of < 0.05.

Results

Patient Characteristics

Among the 38 patients eligible for the study, one died during angioplasty from cardiogenic shock and two were lost to follow up after hospital discharge. The clinical and angiographic characteristics of the 35 patients included are summarised in table 1.

Myocardial Contrast Echocardiography

Contrast coronary reflow

Twenty patients (57%) had more than 75% of the risk area uniformly opacified with contrast after angiographic reperfusion of the infarct related coronary artery (contrast reflow), whereas 15 patients (43%) had a residual contrast defect of more than 25% (contrast no reflow). A residual contrast defect of more than 50% of the risk area was observed in six patients (17%). Table 2 summarises the characteristics of these two groups. Only a greater left ventricular ejection fraction was statistically associated with the presence of a contrast reflow (p < 0.05).

Contrast collateral blood flow

Significant contrast collateral blood flow was observed before reperfusion in 14 patients (40%) and was not statistically associated with the presence of angiographically confirmed collateral blood flow (p = 0.39). Clinical and angiographic characteristics did not differ significantly between patients with and without the presence of contrast collateral flow (table 2).

Dobutamine and Follow Up

Echocardiography

Functional recovery with dobutamine was more often observed in patients with reflow than in those without reflow (p = 0.04) and was statistically associated with recovery of contractile function at follow up (p = 0.03).

Mean wall motion score index with dobutamine (1.32 v 1.44 at baseline; p < 0.05) and at follow up (1.26; p < 0.05 v baseline) improved in the patients with contrast collateral blood flow, whereas no significant change was observed in the patients without contrast collateral flow. The presence of contrast collateral blood flow was also statistically associated with improvement of segmental function with dobutamine (p = 0.04) and at follow up (p = 0.04).

Prediction of Reversible Dysfunction at Two Month Follow Up

Myocardial contrast echocardiography

Contrast reflow and contrast collateral blood flow evaluated alone or in combination were both associated with recovery of function at follow up (p < 0.05; table 3). Figure 1 is an example of a patient with anterior myocardial infarction related to left anterior descending coronary artery occlusion and with collateral flow originated from the right coronary artery. This patient had reversible contractile dysfunction at two month follow up echocardiography. Table 4 summarises the sensitivity, specificity, and negative and positive predictive values of myocardial contrast echocardiography—with and without combining the assessment of reflow and collateral blood flow—in predicting recovery of contractile function at two months. Presence of either reflow (“strong” criterion) or collateral blood flow was highly sensitive (100%) of recovery of segmental function at follow up. The use of the weak reflow criterion (> 50% of the risk area reperfused with contrast) was very sensitive (100%) but poorly specific (30%) of contractile reserve at follow up.

Myocardial contrast v dobutamine echocardiography

Myocardial contrast echocardiography had a lower specificity than dobutamine echocardiography with respect to the presence of myocardial viability at follow up (60% v 90%; table 4). Only the simultaneous presence of contrast reflow and contrast collateral blood flow resulted in similar values of specificity for the two tests (90%) without decreasing sensitivity. Dobutamine echocardiography remained less sensitive than myocardial contrast echocardiography (60% v 100%).

Table 3  Contrast echocardiography results regarding recovery of segmental function at two month follow up

<table>
<thead>
<tr>
<th>Contrast echocardiography</th>
<th>Improved contraction</th>
<th>Unchanged contraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reflow (n = 20, 57%)</td>
<td>14 (70)</td>
<td>6 (30)</td>
</tr>
<tr>
<td>No reflow (n = 15, 43%)</td>
<td>4 (27)</td>
<td>11 (73)</td>
</tr>
<tr>
<td>Collateral flow (-) (n = 21, 60%)</td>
<td>7 (33)</td>
<td>14 (67)</td>
</tr>
<tr>
<td>Reflow and/or collateral (+) (n = 21, 60%)</td>
<td>15 (71)</td>
<td>6 (29)</td>
</tr>
<tr>
<td>Reflow and collateral (+) (n = 8, 23%)</td>
<td>6 (75)</td>
<td>2 (25)</td>
</tr>
<tr>
<td>No reflow and collateral (-) (n = 6, 17%)</td>
<td>0</td>
<td>6 (100)</td>
</tr>
</tbody>
</table>

Values are n (%).
Lower mean age (51 ± 59 years; p = 0.02), absence of previous angina (p = 0.007), and lower mean wall motion score index at two months (1.26 (0.18) v 1.45 (0.23); p = 0.04) were the only clinical variables statistically associated with presence of myocardial viability at the two month follow up.

**Discussion**

The main results of our study were first, that myocardial reflow and collateral blood flow, evaluated by myocardial contrast echocardiography shortly after reperfusion of acute myocardial infarction, were both statistically associated with recovery of contractile function at a two month follow up; second, that the combined assessment of these two variables is highly sensitive (100%) for myocardial viability, without decreasing the specificity of the test; and third, that dobutamine echocardiography remains more specific than contrast echocardiography in predicting myocardial viability (90% v 60%). Only the simultaneous presence of reflow and collateral blood flow using contrast echocardiography achieved values of specificity similar to that of dobutamine echocardiography.

**MYOCARDIAL CONTRAST NO REFLOW AFTER ACUTE MYOCARDIAL INFARCTION**

The air filled bubbles used for myocardial contrast echocardiography have intravascular rheology similar to that of red cells (“microvascular tracer”) and can be used safely in the acute phase of myocardial infarction to evaluate the presence of intramyocardial reflow, a fundamental prerequisite for myocardial viability. Although hyperaemia occurring in the early phase of reflow leads classically to an underestimation of irreversibly damaged microvasculature, Villanueva et al showed that the contrast defect size (no reflow area) correlated with infarct size 15 minutes after reperfusion of experimental myocardial infarction. Ito et al, who performed myocardial contrast echocardiography before and shortly after coronary reperfusion, also observed a good correlation between contrast reflow and patient prognosis, particularly with regard to congestive heart failure. In our study, the no reflow phenomenon was observed in 15 patients (43%), more commonly than reported recently by Ito et al (37%), and much more commonly than observed by Illiceto et al (25%) or Ito et al in their original publication (25%), where no reflow was defined as a residual contrast defect involving more than 50% of the risk area after reperfusion. Using this latter definition, however, this phenomenon was observed in six (17%) of our patients. As did other investigators, we observed that no reflow was statistically more common in larger infarcts (lower mean ejection fraction and higher mean wall motion score index) and that, conversely, the presence of reflow was statistically associated with both contractile reserve by dobutamine echocardiography and recovery of regional function at follow up.

**Table 4 Diagnostic accuracy of dobutamine echocardiography and myocardial contrast echocardiography for prediction of improvement of contractile function at two month follow up**

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine echocardiography</td>
<td>60</td>
<td>90</td>
<td>86</td>
<td>69</td>
</tr>
<tr>
<td>Contrast reflow 75%</td>
<td>70</td>
<td>60</td>
<td>64</td>
<td>67</td>
</tr>
<tr>
<td>Contrast reflow 50%</td>
<td>100</td>
<td>30</td>
<td>58</td>
<td>100</td>
</tr>
<tr>
<td>Contrast collateral flow (+)</td>
<td>60</td>
<td>70</td>
<td>64</td>
<td>63</td>
</tr>
<tr>
<td>Contrast reflow 75% and/or collateral flow</td>
<td>100</td>
<td>60</td>
<td>69</td>
<td>100</td>
</tr>
<tr>
<td>Contrast reflow 75% and collateral flow</td>
<td>45</td>
<td>90</td>
<td>73</td>
<td>62</td>
</tr>
</tbody>
</table>

Reflow 75%, 75% of the risk area reperfused with contrast (“strong criterion”). Reflow 50%, 50% of the risk area reperfused with contrast (“weak criterion”). PPV, positive predictive value; NPV, negative predictive value.

**COMBINED ASSESSMENT OF REFLOW AND COLLATERAL BLOOD FLOW BY MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY**

Because the size of the bubbles of the sonicated agents (7 to 10 µm) is small enough to resolve...
most collateral vessels, myocardial contrast echocardiography may be the most suitable technique for the assessment of collateral flow.20 28 31 Even though the development of collateral channels usually requires several hours after coronary occlusion, beneficial effects of angiographically identified collateral vessels on left ventricular function have been reported within two to eight hours after the onset of symptoms.25 31 Thus significant contrast collateral flow was observed in 14 of our patients (40%) and, as in the results of Sabia et al., this finding was associated with reversible dysfunction at follow up but did not correlate with the collateral vessel grade determined angiographically (p = 0.04). However, in our study—and reported for the first time to our knowledge—the combined assessment of reflow and collateral blood flow after acute reperfused myocardial infarction enhanced the sensitivity of myocardial contrast echocardiography for detecting reversible dysfunction, without decreasing the specificity of the test (100% sensitivity in presence of either reflow or collateral blood flow, v 70% with reflow alone and 60% with collateral flow alone; table 4). The sensitivity of reflow alone in our study (70%) was lower than the results observed by Iliceto et al or Agati et al (100%), but this difference is probably related to different definitions of reflow in these studies.25 31 In our study, the choice of the strong criterion to define reflow (more than 75% of the risk area opacified by contrast) decreased the sensitivity but enhanced the specificity of the test (60%, v 46% observed by Iliceto et al). The combined assessment of reflow and collateral blood flow resulted in high sensitivity of myocardial contrast echocardiography for myocardial viability, whereas the choice of the strong criterion to define reflow resulted in better specificity (table 4). Thus the combined evaluation of reflow and collateral flow enhanced the accuracy of myocardial contrast echocardiography in predicting functional recovery, which seems to be particularly relevant in patients with depressed left ventricular function.35 Since residual blood flow would maintain myocardial cell viability for a prolonged period, our results confirm that collateral flow within the occluded bed may be an important factor in determining infarct size in humans.27 30 31 By increasing the accuracy of the test, the combined assessment of reflow and collateral blood flow using contrast echocardiography may improve the identification of high risk patients, who are most susceptible to developing ventricular remodelling and heart failure.7 Further studies are needed, however, to define the role of early vasodilator treatment in these patients.

CONTRAST RESERVE v MICROVASCULAR INTEGRITY IN PREDICTING RECOVERY OF SEGMENTAL DYSFUNCTION
Perfusion may overestimate the amount of myocardial salvage, particularly during the early hours after reperfusion, and thus myocardial contrast echocardiography is less specific than dobutamine echocardiography in predicting myocardial viability.7 25 34 36 37 Bolognese et al recently showed that contrast enhancement shortly after reflow did not necessary imply functional recovery in the chronic stage.7 They also showed that contractile reserve elicited by dobutamine echocardiography was more accurate than early reperfusion as assessed by myocardial contrast echocardiography in predicting functional recovery in patients reperfused by direct angioplasty. One explanation for these findings is that areas that are defined as non-viable by dobutamine echocardiography and have reflow with contrast echocardiography are areas with metabolism but no function.7 Our results are quite similar when the no reflow phenomenon was considered on its own. However, combined evaluation of reflow and collateral blood flow allows a high sensitivity (100%) and negative predictive value (100%) to be achieved, with a specificity (60%) and positive predictive value (64%) better than those obtained by Bolognese et al (18% and 41%, respectively). Even though combined assessment of reflow and collateral flow by contrast echocardiography still yields suboptimal information for predicting functional recovery, evaluation of these two variables enhanced the accuracy of the test compared with evaluating reflow alone (table 4). Because the extent of collateral flow within the occluded bed was one of the main determinants of final infarct size,10 26 the combined assessment of reflow and collateral flow was probably more representative of “myocardium at risk” and thus explain our results. The difference in the results observed between contrast and dobutamine echocardiography may partly be explained by differences in the timing of the tests. The relatively low sensitivity of dobutamine echocardiography in our study compared with previous results was probably linked to inclusion of inferoposterior myocardial infarcts (43% of patients) and to the use of harder criteria of myocardial viability with dobutamine echocardiography (improvement of wall motion in at least two contiguous dysynergic segments) which enhances the specificity but may decrease the sensitivity of the test.7 34

STUDY LIMITATIONS
Coronary angiography was not performed systematically at follow up and therefore reclosure or restenosis—which may alter functional recovery—cannot definitely be excluded. Contrast collateral blood flow was evaluated qualitatively (that is, present or absent) and not as a percentage of the infarct bed perfused by the non-infarct-related coronary artery.10 26 However, Sabia et al observed that only patients in whom more than 50% of the infarct bed was supplied by collateral flow had improved function at follow up.26 We therefore chose this definition of “significant collateral blood flow.” For clinical routine, particularly in patients treated with thrombolysis, the intravenous administration of contrast may be a very promising way of evaluating perfusion non-invasively.5 35 In the setting of an acute myocardial infarct reperfused by direct angioplasty, the intracoronary injection of contrast in the guiding catheter...
Reflow and collateral flow assessed by contrast echocardiography

CONCLUSIONS
Combined assessment of reflow and collateral blood flow shortly after reperfusion of acute myocardial infarction enhanced the sensitivity of myocardial contrast echocardiography for identifying the presence of reversible contractile dysfunction. The simultaneous presence of reflow and collateral blood flow is as specific as contractile reserve evaluated by dobutamine echocardiography. This direct, rapid, and safe assessment of myocardial viability using myocardial contrast echocardiography may be a help in the evaluation of prognosis immediately after angiographic reperfusion.

18 Kaul S. Clinical applications of myocardial contrast echocardiography. Am J Cardiol 1992;69:45–55H.
Combined assessment of reflow and collateral blood flow by myocardial contrast echocardiography after acute reperfused myocardial infarction

F Leclercq, P Messner-Pellenc, Q Descours, J-P Daures, J-L Pasquié, F-X Hager, J-M Davy and R Grolleau-Raoux

Heart 1999 82: 62-67
doi: 10.1136/hrt.82.1.62

Updated information and services can be found at:
http://heart.bmj.com/content/82/1/62

These include:

References
This article cites 36 articles, 17 of which you can access for free at:
http://heart.bmj.com/content/82/1/62#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Clinical diagnostic tests (4779)
- Echocardiography (2127)
- Acute coronary syndromes (2742)
- Drugs: cardiovascular system (8842)
- Interventional cardiology (2933)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/